Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.
HIGHLIGHTS
* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating |
* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating |
* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 |
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order
* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating |
* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating |
* BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3 |
* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 |
* Emergent Biosolutions EBS.N: H.C. Wainwright initiates coverage with buy rating; PT $15 |
* Exelixis Inc EXEL.O: RBC raises target price to $38 from $34 |
* Insulet Corp PODD.O: BTIG raises target price to $300 from $270 |
* Metavia Inc MTVA.O: H.C. Wainwright initiates coverage with buy rating; PT $12 |
* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。